Information Provided By:
Fly News Breaks for September 6, 2017
BCRX
Sep 6, 2017 | 08:12 EDT
Jefferies analyst Maury Raycroft upgraded BioCryst Pharmaceuticals to Buy from Hold and raised his price target for the shares to $7 from $5. The final APeX-1 data readout gives BCX7353 a better chance of success in a Phase III trial, Raycroft tells investors in a research note. Further, the analyst sees increased potential for eventual approval given the need for an oral option. Raycroft views BioCryst shares as undervalued. JPMorgan last night also upgraded BioCryst.
News For BCRX From the Last 2 Days
BCRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.